Users Online: 678 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
 

 

Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
     
REVIEW ARTICLE
Year : 2020  |  Volume : 64  |  Issue : 6  |  Page : 125-127

Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?


1 Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India
2 Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India

Correspondence Address:
Aditya Prasad Dash
Central University of Tamil Nadu, Tiruvarur, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijph.IJPH_496_20

Rights and Permissions

Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed19157    
    Printed121    
    Emailed0    
    PDF Downloaded737    
    Comments [Add]    

Recommend this journal